PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31961053-10 2020 In conclusion, resistance to ALK-TKIs based on secondary mutation in this study was similar to that in previous reports, except for crizotinib resistance. crizotinib 132-142 ALK receptor tyrosine kinase Homo sapiens 29-32 32048771-0 2020 Phase Ib Study of Crizotinib Plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation. crizotinib 18-28 ALK receptor tyrosine kinase Homo sapiens 127-130 32048771-1 2020 LESSONS LEARNED: This study evaluating first-line crizotinib plus pembrolizumab in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) was terminated early because increased availability of second-generation ALK inhibitors resulted in difficulty identifying and accruing eligible patients. crizotinib 50-60 ALK receptor tyrosine kinase Homo sapiens 97-123 32048771-1 2020 LESSONS LEARNED: This study evaluating first-line crizotinib plus pembrolizumab in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) was terminated early because increased availability of second-generation ALK inhibitors resulted in difficulty identifying and accruing eligible patients. crizotinib 50-60 ALK receptor tyrosine kinase Homo sapiens 125-128 32048771-5 2020 BACKGROUND: Previous research suggests single-agent crizotinib is efficacious for the treatment of anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer (NSCLC). crizotinib 52-62 ALK receptor tyrosine kinase Homo sapiens 99-125 32048771-5 2020 BACKGROUND: Previous research suggests single-agent crizotinib is efficacious for the treatment of anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer (NSCLC). crizotinib 52-62 ALK receptor tyrosine kinase Homo sapiens 127-130 32048771-6 2020 METHODS: This study evaluated the safety and preliminary antitumor activity of crizotinib plus pembrolizumab as first-line therapy in patients with ALK-rearranged NSCLC. crizotinib 79-89 ALK receptor tyrosine kinase Homo sapiens 148-151 32069373-6 2020 ALK gene alterations have rendered tumours insensitive to crizotinib. crizotinib 58-68 ALK receptor tyrosine kinase Homo sapiens 0-3 31615346-0 2020 How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? crizotinib 28-38 ALK receptor tyrosine kinase Homo sapiens 42-45 31971859-4 2020 The first-generation ALK inhibitor crizotinib is approved in the front-line setting for the treatment of advanced NSCLC; unfortunately, these tumors may eventually develop resistance to this molecule. crizotinib 35-45 ALK receptor tyrosine kinase Homo sapiens 21-24 31894386-7 2020 We also identified rare ALK fusions, including CHRNA7-ALK, TACR1-ALK, HIP1-ALK, DYSF-ALK and ITGAV-ALK, in patients with early-onset disease, and patients with these fusions responded well to crizotinib treatment. crizotinib 192-202 ALK receptor tyrosine kinase Homo sapiens 24-27 31894386-10 2020 CONCLUSION: Unique genetic characteristics were found in ALK-rearranged NSCLC patients with early disease onset, and these patients responded better to crizotinib and had longer PFS compared to patients with later disease onset. crizotinib 152-162 ALK receptor tyrosine kinase Homo sapiens 57-60 31712133-8 2020 Sixteen out of 32 patients (50%) with ALK resistance mutations to crizotinib achieved an investigator-assessed response to alectinib (all partial responses); most of these ALK mutations were known to be sensitive to alectinib. crizotinib 66-76 ALK receptor tyrosine kinase Homo sapiens 38-41 31712133-8 2020 Sixteen out of 32 patients (50%) with ALK resistance mutations to crizotinib achieved an investigator-assessed response to alectinib (all partial responses); most of these ALK mutations were known to be sensitive to alectinib. crizotinib 66-76 ALK receptor tyrosine kinase Homo sapiens 172-175 31712133-10 2020 CONCLUSION: Alectinib appears clinically active against ALK rearrangements and mutations, as well as several ALK variants that can cause resistance to crizotinib. crizotinib 151-161 ALK receptor tyrosine kinase Homo sapiens 109-112 31924369-0 2020 Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinib. crizotinib 130-140 ALK receptor tyrosine kinase Homo sapiens 23-26 31721468-5 2020 METHODS: This is a retrospective single-center study and enrolled 113 staged IIIB-IV ALK-positive NSCLC patients who had received crizotinib treatment. crizotinib 130-140 ALK receptor tyrosine kinase Homo sapiens 85-88 31721468-12 2020 CONCLUSIONS: Trend of NLR, dNLR, PLR and WBC could be used to identify patients progress status in ALK-positive NSCLC patients receiving crizotinib. crizotinib 137-147 ALK receptor tyrosine kinase Homo sapiens 99-102 31756496-0 2020 Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. crizotinib 14-24 ALK receptor tyrosine kinase Homo sapiens 36-39 31756496-1 2020 INTRODUCTION: We report updated data from a phase 2 randomized study evaluating brigatinib in crizotinib-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). crizotinib 94-104 ALK receptor tyrosine kinase Homo sapiens 116-142 31756496-1 2020 INTRODUCTION: We report updated data from a phase 2 randomized study evaluating brigatinib in crizotinib-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). crizotinib 94-104 ALK receptor tyrosine kinase Homo sapiens 144-147 31721468-0 2020 The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib. crizotinib 129-139 ALK receptor tyrosine kinase Homo sapiens 62-65 31820329-1 2020 BACKGROUND: Crizotinib, ceritinib, and alectinib improved survival in patients with anaplastic lymphoma kinase (ALK) arrangement non-small-cell lung cancer (NSCLC); however, the long-term economic outcomes of using ceritinib and alectinib versus crizotinib are still unclear. crizotinib 12-22 ALK receptor tyrosine kinase Homo sapiens 84-110 31820329-1 2020 BACKGROUND: Crizotinib, ceritinib, and alectinib improved survival in patients with anaplastic lymphoma kinase (ALK) arrangement non-small-cell lung cancer (NSCLC); however, the long-term economic outcomes of using ceritinib and alectinib versus crizotinib are still unclear. crizotinib 12-22 ALK receptor tyrosine kinase Homo sapiens 112-115 31906956-0 2020 Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report. crizotinib 0-10 ALK receptor tyrosine kinase Homo sapiens 68-71 31706006-1 2020 Crizotinib is a multi-target receptor tyrosine kinase inhibitor which is of great importance for the management of ALK-rearranged non-small cell lung cancer (NSCLC) patients. crizotinib 0-10 ALK receptor tyrosine kinase Homo sapiens 115-118 32021525-5 2020 Here we report two ALK-rearranged NSCLC patients who developed radiation necrosis shortly after initiating lorlatinib following progression on the sequential treatment of crizotinib, alectinib, and brigatinib. crizotinib 171-181 ALK receptor tyrosine kinase Homo sapiens 19-22 31906956-3 2020 Here, we report a case of osteitis induced by an ALK inhibitor mimicking bone metastasis, a previously undescribed side effect of crizotinib. crizotinib 130-140 ALK receptor tyrosine kinase Homo sapiens 49-52 31906956-4 2020 CASE PRESENTATION: A 31-year-old woman with stage IV ALK-rearranged NSCLC presented with back pain after 3 months of crizotinib treatment. crizotinib 117-127 ALK receptor tyrosine kinase Homo sapiens 53-56 31906956-10 2020 Crizotinib differs from other ALK inhibitors as it targets other kinases as well, which may have been responsible for the osteitis. crizotinib 0-10 ALK receptor tyrosine kinase Homo sapiens 30-33 31569004-0 2019 Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants. crizotinib 97-107 ALK receptor tyrosine kinase Homo sapiens 66-69 31766077-1 2020 A 47-year-old female with ALK-rearranged lung adenocarcinoma developed leptomeningeal metastasis (LM) after progression on first-line crizotinib. crizotinib 134-144 ALK receptor tyrosine kinase Homo sapiens 26-29 31852910-5 2019 A phase I clinical trial of the first generation ALK inhibitor, crizotinib, in neuroblastoma patients showed modest results and suggested that further investigation was needed. crizotinib 64-74 ALK receptor tyrosine kinase Homo sapiens 49-52 31654622-1 2019 Non-small cell lung cancer with ALK rearrangements can be targeted effectively with ALK inhibitors such as crizotinib. crizotinib 107-117 ALK receptor tyrosine kinase Homo sapiens 32-35 31654622-1 2019 Non-small cell lung cancer with ALK rearrangements can be targeted effectively with ALK inhibitors such as crizotinib. crizotinib 107-117 ALK receptor tyrosine kinase Homo sapiens 84-87 31690489-0 2020 Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma. crizotinib 34-44 ALK receptor tyrosine kinase Homo sapiens 63-66 31958984-1 2020 Aim: To assess the cost-effectiveness of crizotinib verses platinum-based doublet chemotherapy as the first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) in the real-world setting. crizotinib 41-51 ALK receptor tyrosine kinase Homo sapiens 127-153 31958984-1 2020 Aim: To assess the cost-effectiveness of crizotinib verses platinum-based doublet chemotherapy as the first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) in the real-world setting. crizotinib 41-51 ALK receptor tyrosine kinase Homo sapiens 155-158 31958984-7 2020 Results: Crizotinib improved PFS versus chemotherapy in ALK positive patients (median PFS 19.67 m vs 5.47 m; p < 0.001). crizotinib 9-19 ALK receptor tyrosine kinase Homo sapiens 56-59 31958984-13 2020 Conclusion: Crizotinib could be an effective, and cost-effective first-line treatment for ALK positive advanced NSCLC with the MI coverage currently available in Chengdu, Sichuan Province, China. crizotinib 12-22 ALK receptor tyrosine kinase Homo sapiens 90-93 31569004-7 2019 Taken together, this work provided a promising ALK inhibitor to circumvent the clinical crizotinib-resistant mutants. crizotinib 88-98 ALK receptor tyrosine kinase Homo sapiens 47-50 31696059-0 2019 Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center. crizotinib 25-35 ALK receptor tyrosine kinase Homo sapiens 57-60 31857951-2 2019 The therapeutic strategy depends on anti-ALK tyrosine kinase inhibitors (TKIs) of which crizotinib was the first approved for clinical use. crizotinib 88-98 ALK receptor tyrosine kinase Homo sapiens 41-44 31696059-2 2019 Methods: We reviewed the medical records of crizotinib-treated NSCLC patients with ALK-rearrangement between May 2014 and May 2018 at Fudan University Shanghai Cancer Center. crizotinib 44-54 ALK receptor tyrosine kinase Homo sapiens 83-86 31696059-15 2019 Conclusions: Crizotinib was effective and well tolerated in Chinese patients with ALK-positive, advanced NSCLC in real-world clinical practice. crizotinib 13-23 ALK receptor tyrosine kinase Homo sapiens 82-85 31656659-0 2019 Real world experience on treatment, outcome and toxicity of crizotinib in patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer. crizotinib 60-70 ALK receptor tyrosine kinase Homo sapiens 88-114 31558238-0 2019 Rapid Postoperative Relapse in ALK-Positive Locally Advanced NSCLC Patient with Complete Pathological Response to Neoadjuvant Crizotinib. crizotinib 126-136 ALK receptor tyrosine kinase Homo sapiens 31-34 31933785-4 2019 Since the tumor was spreading all over the abdominal cavity and ALK staining of the tumor was positive, crizotinib was suggested as adjuvant therapy. crizotinib 104-114 ALK receptor tyrosine kinase Homo sapiens 64-67 31656659-1 2019 Background: Crizotinib has been the standard treatment for patients with anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer (NSCLC). crizotinib 12-22 ALK receptor tyrosine kinase Homo sapiens 73-99 31656659-1 2019 Background: Crizotinib has been the standard treatment for patients with anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer (NSCLC). crizotinib 12-22 ALK receptor tyrosine kinase Homo sapiens 101-104 31656659-22 2019 Conclusions: This retrospective analysis of a real-world experience confirms the therapeutic benefit of crizotinib in advanced ALK-positive NSCLC. crizotinib 104-114 ALK receptor tyrosine kinase Homo sapiens 127-130 31616158-5 2019 In recent years, multiple ALK inhibitors have been developed to treat NSCLC, including the first-generation tyrosine kinase inhibitor (TKI) crizotinib; second-generation TKIs such as ceritinib, ensartinib, brigatinib, and alectinib; the third-generation TKI lorlatinib; and the fourth-generation TKI repotrectinib. crizotinib 140-150 ALK receptor tyrosine kinase Homo sapiens 26-29